Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement

Luxiang Shang, Yujiao Zhang, Yang Zhao, Baopeng Tang, Yinglong HouBioScience 2022 · DOI

TL;DR

Despite international guidelines recommending oral anticoagulants (OACs) as the gold standard for preventing strokes in patients with atrial fibrillation (AF), China faces a significant implementation gap. This review highlights that while OAC use is rising, it remains hampered by low prescription rates, inappropriate dosing, and poor patient adherence, necessitating a "whole-of-system" approach to improve clinical outcomes.

What Problem Does This Paper Address?

Atrial fibrillation—a common heart rhythm disorder—is a major driver of ischemic stroke, disability, and death. In China, the burden is particularly acute: an aging population and rapid urbanization have led to an estimated 20 million cases. While OAC therapy (including traditional Vitamin K antagonists like warfarin and newer non-VKA oral anticoagulants, or NOACs) can drastically reduce stroke risk, its real-world application in China is suboptimal.

The authors tackle the "why" behind this gap, exploring the obstacles at the physician, patient, and policy levels. They aim to provide a roadmap for moving from "knowing what to do" (guidelines) to "actually doing it" (clinical practice) within the unique context of the Chinese healthcare system.

Methods

This paper is a narrative review. Rather than conducting a new clinical trial, the authors synthesized data from a wide array of existing literature published between 2003 and 2022. They compared domestic Chinese data against international benchmarks and global registries to identify specific deficiencies in the Chinese care model. The review categorizes obstacles into three main buckets: physician-related, patient-related, and drug-related factors.

Datasets

The authors drew from several high-profile datasets and registries, including:

  • Global Registries: GARFIELD-AF and GLORIA-AF (Phase I and II), which provide a basis for international comparison.
  • National Chinese Surveys: The China Hypertension Survey, the China National Stroke Screening Survey, and the China Registry of Atrial Fibrillation.
  • Hospital-Based Data: Data from the China AF Center (covering 362 hospitals) and the Hospital Prescription Analysis Corporation Program of China.
  • Regional Studies: Specific epidemiological data from Beijing, Shanghai, and various provinces to highlight regional disparities.

Key Insights and Ideas

  • The "Tertiary Bias": Most data showing improved OAC use comes from top-tier (tertiary) hospitals. In community and rural settings, OAC use remains alarmingly low—sometimes as low as 2% to 6% for high-risk patients.
  • The Primary Care "Weak Link": A significant hurdle is the lack of AF management knowledge among emergency physicians and general practitioners. Up to 70-80% of primary care doctors were found to be unfamiliar with standard stroke risk assessment tools (like the CHA₂DS₂-VASc score).
  • Bleeding Phobia: Both patients and physicians in China exhibit a high "fear of bleeding," leading to "inappropriate under-dosing"—prescribing doses lower than what is clinically effective to avoid side effects, which ironically leaves the patient unprotected from stroke.
  • Adherence vs. Persistence: The paper clarifies a common confusion: adherence (taking the medicine correctly) and persistence (staying on the medicine long-term). In China, both are poor, with 1-year persistence rates often hovering around 50%.
  • The NOAC Revolution: NOACs are rapidly overtaking warfarin in China, spurred by their inclusion in national insurance and centralized procurement policies that have slashed costs.

Key Results

  • Prevalence: AF prevalence in Chinese adults is roughly 1.6%, representing a massive public health challenge.
  • OAC Uptake: While hospital-based studies show OAC use has climbed to roughly 64.8% in recent years, community-based samples show the reality is likely much lower for the general population.
  • Dosing Accuracy: Less than 50% of patients on OACs are receiving the appropriate dose according to guidelines.
  • Economic Impact: The cost of NOACs (like dabigatran) was previously a major barrier, but recent government-led price negotiations have made these drugs significantly more accessible.

Limitations and Future Work

The authors acknowledge that much of the current data is "manually entered" into registries by tertiary centers, which likely leads to an overestimation of the true quality of care across the country.

Future directions include: 1. Digital Health: Leveraging mobile apps (like the WeChat-based "mAF" platform) to improve patient education and follow-up. 2. Hierarchical Care: Establishing a "top-down" training model where specialists in major hospitals support and educate primary care physicians. 3. Home-Grown Evidence: Moving away from relying solely on Western clinical trials and conducting more large-scale studies specifically on Chinese populations to refine dosing guidelines. 4. Policy Integration: Utilizing national medical insurance databases for real-time monitoring of OAC usage to identify and fix regional gaps.

Summary updated

Abstract

Atrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving OACs, however, still much lower than those in other countries and regions. Moreover, the phenomenon of inappropriate OAC prescribing and poor long-term persistence and adherence with OAC therapy in AF patients in China have also been noted. The 1-year adherence and persistence of OACs are as low as 50%. Multiple factors from the physicians, patients, and OAC drugs contribute to these phenomena. The management of OACs in AF patients in China needs to be further improved by the joint efforts of healthcare administration (policy makers) and health systems including medical associations, hospitals, and physicians.
BibTeX
@inproceedings{shang2022contemporary,
  author = {Luxiang Shang and Yujiao Zhang and Yang Zhao and Baopeng Tang and Yinglong Hou},
  title = {{Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement}},
  booktitle = {BioScience},
  year = {2022},
  doi = {10.5582/bst.2022.01278},
}
Figure